Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - OTC Markets Other stock markets 20:55:53 28/05/2026 +03			5-day change	1st Jan Change
0.000100 ^USD	-98.33%		-.--%	-93.33%

14/08/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/05/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Market Cap	85.73K 74.75K 69.23K 64.81K 122K 8.09M 122K 821K 318K 3.98M 322K 315K 13.83M	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	3.92M 3.41M 3.16M 2.96M 5.55M 370M 5.59M 37.52M 14.54M 182M 14.7M 14.39M 632M	EV / Sales 2021	93,978,853,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

14/08/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/05/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
31/03/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/03/23	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
10/11/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
12/08/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
31/05/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
11/05/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
17/03/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/03/22	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/01/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
18/01/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
11/11/21	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

06/12/23	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
31/03/23	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
21/03/23	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
13/12/22	Rapid Therapeutic Science Laboratories Updates Patents	AQ
10/11/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Rapid Therapeutic Science Laboratories, Inc. Stock

Stocks

RTSL

US7534312043

Pharmaceuticals

Valuation: Rapid Therapeutic Science Laboratories, Inc.

Chart: Rapid Therapeutic Science Laboratories, Inc.

Latest news : Rapid Therapeutic Science Laboratories, Inc.

Press Releases: Rapid Therapeutic Science Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Rapid Therapeutic Science Laboratories, Inc.

Latest insider transactions

Alternative Medicine

Financials

Company Profile

1 day	-98.33%
1 month	-98.33%
3 months	-98.33%
6 months	-93.33%
Current year	-93.33%

1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		0.08
5 years	0		16.25
10 years	0		125

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	15/11/2019
D. Watler DFI	Director of Finance/CFO	77	15/11/2019

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	15/11/2019
Donal Schmidt BRD	Director/Board Member	65	15/11/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/12/21	Texas Mdi, Inc.	Don	Company	2,000,000	1.0332%
27/12/21	Sean Berrier	Don	Executive/Senior Manager	2,000,000	1.0332%
27/08/21	Henry Punzi	Other	Director	125,000	0.0646%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.02 0 0 0.09	-
Net income	-2.87M -2.5M -2.32M -2.17M -4.07M -271M -4.09M -27.47M -10.65M -133M -10.77M -10.53M -462M	-1.79M -1.56M -1.45M -1.36M -2.54M -169M -2.56M -17.19M -6.66M -83.35M -6.74M -6.59M -289M
Net Debt	1.79M 1.56M 1.45M 1.36M 2.54M 169M 2.56M 17.18M 6.66M 83.27M 6.73M 6.59M 289M	3.83M 3.34M 3.09M 2.9M 5.43M 361M 5.46M 36.7M 14.22M 178M 14.38M 14.07M 618M

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	-98.33%	-.--%	-98.65%	-99.87%	1.9K
YUNNAN BAIYAO GROUP CO.,LTD	-0.98%	-4.29%	-11.99%	-8.50%	12.77B
BEIJING TONGRENTANG CO., LTD	-1.84%	-5.81%	-34.45%	-58.68%	4.76B
DONG-E-E-JIAO CO., LTD.	-3.47%	-9.51%	-12.31%	-7.72%	4.34B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+0.29%	-1.20%	+15.26%	-17.47%	3.8B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	+0.47%	-4.39%	+7.90%	-43.34%	3.71B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-1.30%	-4.43%	-5.64%	-10.07%	3.53B
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.07%	-2.22%	-8.68%	-2.22%	3.11B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.71%	+0.39%	-3.90%	-25.43%	2.38B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-1.61%	-3.41%	-15.43%	+28.56%	1.67B
Average	-10.75%	-3.49%	-16.79%	-24.47%	4.01B
Weighted average by Cap.	-1.06%	-4.29%	-9.12%	-17.56%